Sagent Pharmaceuticals and Itochu Chemical Frontier Corporation Announce Development and Manufacturing Collaboration
Complete the form below to unlock access to ALL audio articles.
Sagent Pharmaceuticals, Inc. and Itochu Chemical Frontier Corporation (ICF) have announced finalization of a development and supply collaboration. Under the agreement, ICF will supply injectable products for which Sagent will obtain U.S. regulatory approval and market in the United States.
"We are extremely pleased to partner with a global company of Itochu's caliber and skills on these exciting product opportunities," said Jeffrey M. Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals, Inc.
"Sagent is committed to expanding its network of worldwide strategic partnerships to offer the most diverse and extensive pipeline of the highest quality injectable products to our hospital focused customers and we look forward to including ICF amongst our partners."
"ICF looks forward to rapidly expanding our presence in the U.S. market," said Jun Sato, ICF's president and chief executive officer. "We believe that this collaboration combining ICF's experience in the Japanese market with Sagent's U.S. focused injectable selling and marketing capabilities is an optimal path toward achieving this objective."
